Diaceutics PlcLSE: DXRX

Appointment of Nominated Adviser and Broker

· Issued by Diaceutics Plc

Appointment of Nominated Adviser and Broker

Belfast and London, 2 September 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry is pleased to announce the appointment of Canaccord Genuity Limited as the Company's Nominated Adviser and Broker, with immediate effect.

Enquiries: 

​

Diaceutics PLC   

Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees

Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon

diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.